1
|
Zeidler H. [History of reactive arthritis. Historical milestones and future]. Z Rheumatol 2022; 81:692-698. [PMID: 36006472 PMCID: PMC9406267 DOI: 10.1007/s00393-022-01253-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/14/2022] [Indexed: 11/30/2022]
Abstract
The introduction of the term reactive arthritis (ReA) for the joint inflammation observed after infection with Yersinia enterocolitica, in which "a causative pathogen cannot be isolated from the synovial fluid", and the association with the HLA-B27 were the historical milestones for a new classification and assignment to the spondylarthritides (SpA). The division into postinfectious and reactive arthritis proposed in 1976 was put into perspective in the 1990s because of investigations with the newly available molecular biological method of the polymerase chain reaction. Microbial products could be identified from joint samples of patients with ReA. Therefore, it was proposed to abandon the distinction between the two groups of diseases and to prefer the term ReA for both. This created a terminological and nosological issue. On the one hand, there are generally accepted classification and diagnostic criteria for the classical HLA-B27-associated ReA that are assigned to SpA. On the other hand, an increasing number of bacterial pathogens, viruses, amoebas, helminths as well as antiviral and antibacterial vaccinations are described as triggers of arthritis, which have been published under the term ReA. Since the beginning of the SARS-CoV‑2 pandemic, cases of acute post-COVID-19 arthritis have been described, which were also classified as ReA because of comparable clinical features.
Collapse
Affiliation(s)
- H Zeidler
- Medizinische Hochschule Hannover, Carl-Neuberg Str. 1, 30625, Hannover, Deutschland.
| |
Collapse
|
2
|
Kirchhoff TD, Burchert W, Hoff JVD, Zeidler H, Hundeshagen H, Knapp WH, Berding G. [18F]Fluoride PET Indicates Reduced Bone Formation in Severe Glucocorticoid-induced Osteoporosis. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1629797] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryA 61-year-old female patient presenting with mixed connective tissue disease (Sharp syndrome), underwent a long-term high dose glucocorticoid treatment because of multiple organ manifestations. Under steroid therapy she developed severe osteoporosis resulting in multiple fractures. A dynamic [18F]fluoride PET study in this patient revealed reduced fluoride influx in non-fractured vertebrae. This finding corresponds to pathogenetic concepts which propose an inhibition of bone formation as major cause of glucocorticoid-induced osteoporosis. In the light of the presented case it seems to be promising to evaluate the diagnostic benefit of [18F]fluoride PET in osteoporosis.
Collapse
|
3
|
Abstract
AIM No standardized polymerase chain reaction (PCR) assay is available for detection of Chlamydia trachomatis (C. tr.) in synovial fluid (SF) for diagnostic use in clinical practice. This study tested the performance of two optimized molecular biology methods, to determine which is best suited for detecting C. tr. in SF clinical samples from patients with various rheumatologic diseases. METHODS Two DNA extraction methods, i.e., (1) alkaline lysis and (2) QIAEX II Gel Extraction Kit® + cetyltrimethylammonium bromide (CTAB; Qiagen, Hilden, Germany), and C. tr.-omp1-152 bp PCR were tested in SF samples from a total of 329 patients with the following diagnoses: reactive arthritis (ReA; n = 10, 4 patients had posturethritic ReA), undifferentiated arthritis (UA; n = 66), rheumatoid arthritis (RA; n = 169), psoriatic arthritis (PSA; n = 12), and osteoarthritis (OA) n = 72. RESULTS In SF samples, C. tr.-omp1-152 bp PCR in combination with alkaline lysis DNA extraction allowed detection of more C. tr.-positive samples: 3/10 (30%) ReA patients (all with posturethritic ReA) and 20/66 (38%) UA patients were positive, compared to the 0/10 (0%) patients with ReA and 1/66 (2%) with UA detected using the QIAEX II Gel Extraction Kit® + CTAB. Moreover, 2/12 (17%) SF samples from PSA patients tested positive with alkaline lysis. All samples from patients with OA and RA tested negative. CONCLUSION Alkaline lysis in combination with C. tr.-omp1-152 bp PCR emerged as the most sensitive method for identification of C. tr. in clinical SF samples.
Collapse
Affiliation(s)
- J Freise
- Clinic of Pneumology, Medical School Hannover, Hannover, Germany
| | - I Bernau
- Klinikum Bremen Mitte, Bremen, Germany
| | - S Meier
- Clinic of Immunology and Rheumatology, Medical School Hannover, Hannover, Germany
| | - H Zeidler
- Emeritus, Medical School Hannover, Hannover, Germany
| | - J G Kuipers
- Div. of Rheumatology, Rotes Kreuz Krankenhaus, St. Pauli Deich 24, 28199, Bremen, Germany.
| |
Collapse
|
4
|
Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Rudwaleit M, Sieper J. OP0097 Cigarette smoking predicts radiographic progression in the spine in patients with axial spondyloarthritis in a dose-dependent manner. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.1780] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
5
|
Feldtkeller E, Rudwaleit M, Zeidler H. Easy probability estimation of the diagnosis of early axial spondyloarthritis by summing up scores. Rheumatology (Oxford) 2013; 52:1648-1650. [DOI: 10.1093/rheumatology/ket176] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
6
|
Abstract
Methotrexate (MTX) is the most important disease-modifying antirheumatic drug (DMARD) and is recommended by national and international guidelines as the first choice for treatment of rheumatoid arthritis (RA). Recent studies reporting prescription data of MTX captured only patients who were treated by rheumatologists. Therefore, the aim of the present study was to analyse several aspects of the prescription of MTX based on claims data. Outpatient and inpatient diagnoses as well as prescription data was available for 9579 RA patients for the years 2005-2008. Of the patients 45% were treated exclusively with parenteral MTX, 8% were treated exclusively with oral MTX and 48% switched between both forms of application. The average weekly dosage presribed in 70% of the patients was between 10 and 25 mg. The most common DMARD combination was MTX plus leflunomide with 16%. In 16% RA patients were treated with a combination of MTX and TNF-α inhibitors. Glucocorticoids were prescribed temporarily in 81% together with MTX and supplementation with folic acid was given only in 65%. The results of this study provide important insights into the drug supply of MTX to RA patients in the German statutory health care sector. In particular, the high frequency of prescriptions of parenteral MTX and the inadequate prescription of folic acid are different from the recently published multinational recommendations of the 3E initiative for the use of MTX.
Collapse
Affiliation(s)
- J Zeidler
- Forschungsstelle für Gesundheitsökonomie, Leibniz Universität Hannover, Königsworther Platz 1, 30167, Hannover, Deutschland.
| | | | | |
Collapse
|
7
|
Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Rudwaleit M, Sieper J. OP0247 Reduction of radiographic spinal progression in patients with ankylosing spondylitis treated with non-steroidal anti-inflammatory drugs is most evident in the presence of syndesmophytes and active systemic inflammation. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
8
|
Schubert A, Zeidler H, Hahn M, Hackert-Oschätzchen M, Schneider J. Micro-EDM Milling of Electrically Nonconducting Zirconia Ceramics. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/j.procir.2013.03.026] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Heberlein I, Demary W, Bloching H, Braun J, Buttgereit F, Dreher R, Kuhn C, Lange U, Pollähne W, Zink A, Zeidler H, Häntzschel H, Raspe H. Medikamentöse Osteoporoseprophylaxe und -therapie bei Patienten mit rheumatoider Arthritis (ORA-Studie). Z Rheumatol 2011; 70:793-8, 800-2. [DOI: 10.1007/s00393-011-0872-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
10
|
Wassenberg S, Rau R, Zeidler H. A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis - the Low-Dose Prednisolone Trial. Clin Exp Rheumatol 2011; 29:S68-S72. [PMID: 22018187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2011] [Accepted: 09/15/2011] [Indexed: 05/31/2023]
Abstract
Glucocorticoids (GC) have been used to treat rheumatoid arthritis (RA) for more than 60 years. Despite this very long experience, there remains considerable debate concerning the adequate dosing and timing of these medications, primarily because of frequent and sometimes serious side effects, particularly in high doses. GCs are documented to provide immediate symptomatic relief and to decrease signs of inflammation in active disease. At the time when the Low-Dose Prednisolone Trial (LDPT) was designed, no clear evidence was available concerning whether low doses of GCs given over a long period add to slowing of structural damage in RA. The trial was therefore designed to test the hypothesis that even a low dose of prednisolone that was thought to cause no or only very limited harm could slow radiographic progression. The trial therefore included patients with active early RA (disease duration less than two years) who received either prednisolone 5 mg/day or placebo on concomitant DMARD therapy with parenteral gold or methotrexate for two years. Radiographs of hands and feet were taken at baseline, and at 6, 12 and 24 months. Structural damage was assessed using change in the Ratingen score (0-190 scale) as the primary outcome, and change in the Sharp/van der Heijde score (0-448 scale) for additional information concerning the same radiographs. Of 192 patients in the study, 166 were available for intention to treat analysis (ITT), and 76 completed the study per protocol (PP). Progression of the Ratingen score was significantly less at all consecutive time points in the prednisolone group compared to the control group, with the greatest difference after 6 months. At 24 months the increase in score in the prednisolone group was 1.2 ± 3.5, (95% CI 0.4-2.1) and in the placebo group 4.3 ± 6.8 (95% CI 2.7-5.9) (p=0.006, ITT-analysis). This was confirmed by the results of the Sharp/van der Heijde erosion and total score with an increase of the total score of 5.3 ± 10.7 units in the prednisolone compared to 11.4 ± 19.1 in the placebo group (p=0.022) at 24 months. The LDPT trial therefore confirmed that a very low daily dose of 5 mg prednisolone given over two years in combination with background DMARD therapy substantially decreases radiographically detectable damage in patients with early RA.
Collapse
Affiliation(s)
- S Wassenberg
- Evangelisches Fachkrankenhaus Ratingen, Ratingen, Germany.
| | | | | |
Collapse
|
11
|
Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70:1369-74. [DOI: 10.1136/ard.2010.145995] [Citation(s) in RCA: 246] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
12
|
Zeidler H, Amor B. The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress. Ann Rheum Dis 2010; 70:1-3. [DOI: 10.1136/ard.2010.135889] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
13
|
Putschky N, Fasse S, Zeidler H, Pott HG. Physikalische Therapie in der Rheumatologie - Therapieplanung und Verordnungsweise. AKTUEL RHEUMATOL 2010. [DOI: 10.1055/s-0030-1267990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
|
15
|
Zeidler H. Therapieschema der rheumatoiden Arthritis. Die Dreifachkombination Methotrexat plus Sulfasalazin plus Hydroxychloroquin ist mehr als nur eine Alternative zu Leflunomid. AKTUEL RHEUMATOL 2010. [DOI: 10.1055/s-0030-1248294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
16
|
Bugajska J, Brzosko M, Jędryka-Góral A, Głuszko P, Żołnierczyk-Zreda D, Sagan A, Konarska M, Rell-Bakalarska M, Pazdur J, Zeidler H, Rihl M. Psychological stress in rheumatoid arthritis patients: a comparative Polish–German study. Autoimmun Rev 2010; 9:211-5. [DOI: 10.1016/j.autrev.2009.08.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2009] [Accepted: 08/11/2009] [Indexed: 01/21/2023]
|
17
|
Braun J, Zochling J, Märker-Hermann E, Stucki G, Böhm H, Rudwaleit M, Zeidler H, Sieper J. [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]. Z Rheumatol 2009; 65:728-42. [PMID: 17119900 DOI: 10.1007/s00393-006-0119-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
AIM Our aim was to adapt and implement the evidence based recommendations for the management of ankylosing spodylitis (AS) of the "Assessments in AS" (ASAS) International Working Group together with the European League Against Rheumatism (EULAR) within the framework of a competence network (CN) in rheumatology in the German language area. METHODS The ASAS/EULAR project calculated the effective size (ES), rate ratio, number of patients requiring treatment (number needed to treat, NNT) and the incremental cost-effectiveness ratio (ICER). The strength of the recommendations was determined through the evidence level found in the literature, the risk-benefit trade-off and the clinical experience of the experts. The recommendations were recently published in English. All of the centers taking part in the study area Spondyloarthritis (SpA) CN, as well as an additional 35 experts, were sent the English manuscript. All 35 participants were asked to evaluate the ten main management recommendations on a scale from 0 to 10. RESULTS The recommendations encompass the use of drugs such as non-steroid anti-inflammatories (NSAR), which, along with conventional NSAR include coxibs and the parallel application of gastroprotectives, so called disease-modifying anti-rheumatic drugs, biologicals, simple analgesics, local and systematic glucocorticoids, non-drug therapies (such as patient training, medical training therapy and physiotherapy), in addition to surgical treatment methods. Moreover, three general recommendations were formulated and a therapy scheme created, taking into consideration the various clinical manifestations. The strength of the ASAS/EULAR recommendations was generally high. There was a marked consensus between the German speaking experts and the international proposal: a mean of 9.13 with relatively low variation between the recommendations. SUMMARY Ten key recommendations for the treatment of AS were developed. These were strengthened by a systematic search of the literature and by expert consensus. The large group of German speaking experts were largely in agreement with the proposal. This can be seen as a starting point for the dissemination and implementation of the recommendations.
Collapse
Affiliation(s)
- J Braun
- Rheumazentrum-Ruhrgebiet, St. Josefs-Krankenhaus, Landgrafenstrasse 15, 44652, Herne, Deutschland.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Michel BA, Tschumi U, Woolf AD, Zeidler H, Beglinger C, Dalvit G, Felder M, Graf A, Steurer J. [Chronic musculo-skeletal pain in Switzerland: patient care from the view of physicians and patients]. Praxis (Bern 1994) 2009; 98:933-940. [PMID: 19711286 DOI: 10.1024/1661-8157.98.17.933] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A considerable percentage of the population suffers from chronic musculoskeletal pain (CMP) and patient management does not appear to be optimal. The aim of the present investigations was to assess and evaluate epidemiologic data and discover eventual deficits in patient management. This investigation included several sequential steps: First a European study including Switzerland evaluated the prevalence and characteristics of patients with CMP as well as of the treating physicians. The results were discussed and elaborated in two workshops, where general practitioners and patients were included. In a further step the results of these workshops were evaluated again in a telephone survey addressing patients and physicians both in the French and German speaking parts of Switzerland. Considerable deficits were discovered in the management of patients with CMP: In 35% no firm diagnosis was established, the life quality was considerably reduced in about 13 of the patients, the patients' information on their disorders were found to be rather limited, furthermore, there were misconceptions about medical treatment. The two workshops confirmed the results of the first study. The causes of pain often remained unclear, there were considerable communication problems between patient and physician, medical treatment appeared to be inappropriate, and there were deficits in the time management during consultations. The telephone survey confirmed these deficits. In conclusion management of patients with CMP is characterized by considerable deficits such as missing or unclear diagnosis, misconceptions in medical contexts and treatment. Many of the deficits may be improved and call for measures for optimizing the management of patients with CMP.
Collapse
Affiliation(s)
- B A Michel
- Rheumaklinik und Institut für Physikalische Medizin, Universitätsspital Zürich, Zurich.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Zink A, Radbruch A, Zeidler H. [Preface]. Z Rheumatol 2009; 61 Suppl 2:A3. [PMID: 12491113 DOI: 10.1007/s003930200062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
20
|
Luska G, Zeidler H, Stender HS. Chondrokalzinose (Pseudogicht). ROFO-FORTSCHR RONTG 2009. [DOI: 10.1055/s-0029-1229977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Schnarr S, Wahl A, Jurgens-Saathoff B, Mengel M, Kreipe HH, Zeidler H. Nodular fasciitis, erythema migrans, and oligoarthritis: manifestations of Lyme borreliosis caused by Borrelia afzelii. Scand J Rheumatol 2009. [DOI: 10.1080/rhe.31.3.184.186] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
22
|
Zeidler J, Mittendorf T, Vahldiek G, Zeidler H, Merkesdal S. Comparative cost analysis of outpatient and inpatient rehabilitation for musculoskeletal diseases in Germany. Rheumatology (Oxford) 2008; 47:1527-34. [DOI: 10.1093/rheumatology/ken315] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Kuipers JG, Sibilia J, Bas S, Gaston H, Granfors K, Vischer TL, Hajjaj-Hassouni N, Ladjouze-Rezig A, Sellami S, Wollenhaupt J, Zeidler H, Schumacher HR, Dougados M. Reactive and undifferentiated arthritis in North Africa: use of PCR for detection of Chlamydia trachomatis. Clin Rheumatol 2008; 28:11-6. [PMID: 18688674 DOI: 10.1007/s10067-008-0968-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2008] [Revised: 06/02/2008] [Accepted: 07/01/2008] [Indexed: 11/29/2022]
Abstract
Little is known about the possible role of Chlamydia in patients with reactive or unclassified arthritis in North Africa. This study used polymerase chain reaction (PCR) to survey this population. In addition, we compared the results in three different laboratories for PCR analyses for Chlamydia trachomatis (Ct) in synovial fluid (SF) and tissue (ST) from these North African patients with reactive arthritis (ReA), undifferentiated arthritis (UA), and in rheumatoid arthritis (RA) and osteoarthritis (OA). Eight ReA (six posturethritic, two postenteritic), 23 UA, 13 OA, and 12 RA patients were studied in Algeria, Morocco, and Tunisia. Serum, SF, and ST were obtained from each patient. Ct-PCR was performed in the three different laboratories and compared to Ct-serology [microimmunofluorescence (MIF) and anti-hsp60 enzyme-linked immunosorbent assay (ELISA)] performed in one laboratory. The rate of Ct-PCR positivity in SF/ST was low: none out of the eight ReA and three out of 23 UA patients. In the controls, Ct DNA was detected in two OA SF and in one RA SF. There was no concordance for Ct-PCR positivity between the three laboratories. MIF suggested previous Ct infection (IgG-positive) in two out of five posturethritic ReA, none out of one postenteritic ReA, one out of 17 UA, and nine out of 21 RA/OA patients tested. No MIF-positive patient was PCR-positive from SF or ST. However, anti-hsp60 IgG was detected in all four out of four patients positive by PCR and in 11 out of 44 PCR-negative patients (p = 0.002). In this multinational comparative study, the rate of Ct-PCR-positive synovial specimens in North African ReA/UA patients was low. Concordance among the three PCR testing laboratories was poor indicating the need for test standardization. All Ct-PCR-positive patients were found positive by anti-hsp60 IgG serology.
Collapse
Affiliation(s)
- J G Kuipers
- Department of Rheumatology, Rotes Kreuz Krankenhaus, Bremen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Wollenhaupt J, Hülsemann J, Genth-Stolzenburg S, Zeidler H. Qualitätsmanagement der ambulanten Behandlung in der Rheumatologie. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1043676] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
25
|
Zeidler H, Weitzel O, Wilmowsky H. Synoviaanalyse bei entzündlichen und nichtentzündlichen Gelenkerkrankungen*. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1052316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
26
|
|
27
|
Langer H, Zeidler H. Unklares Fieber als differentialdiagnostische Herausforderung in der Rheumatologie. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1047544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
28
|
Raspe H, Zeidler H. Mobile Rheumahilfe Hannover. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1051141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
29
|
Zeidler H. Patientenschulung in der Rheumatologie. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1046651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Zeidler H, Langer H. Krebsrisiko der chronischen Polyarthritis und Therapie mit Immunsuppressiva. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1047998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
31
|
|
32
|
Lautenschläger J, Brückle W, Zeidler H. Klinische und technische Untersuchungsverfahren bei der Generalisierten Tendomyopathie (Fibromyalgie-Syndrom). AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1043739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
33
|
Münch H, Zeidler H. M. Crohn assoziierte seronegative Spondarthritiden*. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1047988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Zeidler H. Aktueller Stand und kritische Wertung der Behandlung mit Auranofin, parenteralem Gold und D-Penicillamin. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1051083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
35
|
Zeidler H. Neue Aspekte der Therapie mit langfristigen Antirheumatika (sog. Basistherapeutika)*. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1047975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
36
|
Miehle M, Zachr J, Zeidler H. Vorwort der Herausgeber der Aktuellen Rheumatologie zum Sonderheft Schilling. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1043608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
37
|
Lautenschläger J, Jendro M, Mau W, Zeidler H. Die Bedeutung des HLA-DRBI-Gens bei der chronischen Polyarthritis. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1043620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Köhler L, Zeidler H, Kuipers J. Aktueller Stand der medikamentösen Therapie der Spondarthritiden und reaktiven Arthritiden. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1043506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
|
40
|
|
41
|
Ambrosini G, Gierend M, Grasedyck K, Lemmel E, Raspe H, Reiter W, Schneider H, Sörensen H, Zeidler H. Der Einfluß von Alter und Komorbidität auf die Inzidenz von unerwünschten Wirkungen unter Piroxicam. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1047973] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
42
|
|
43
|
Zeidler H. Kortikoid-Low-Dose-Therapie aus rheumatologischer Sicht. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1046700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
44
|
|
45
|
Zeidler H. Vergleich von oraler und parenteraler Goldtherapie*. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1051192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
46
|
Kuipers J, Zeidler H. Das Felty-Syndrom und Tγ-lymphoproliferative Syndrom: Aktuelle Aspekte der Diagnose,Differentialdiagnose und Therapie. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1047318] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
47
|
Schöffski O, Ruof J, Pirk O, Schulenburg J, Zeidler H. Topisches Diclofenac versus orale NSAR in der Therapie der Gonarthrose und Fingerarthrose - Eine Kostenanalyse. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1043511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
48
|
Müller-Faßbender H, Kaik D, Rau R, Schattenkirchner M, Zeidler H. Auranofin (Ridaura®) und Natriumaurothiomalat (Tauredon®) bei der Behandlung der chronischen Polyarthritis. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1051092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
49
|
Zeidler H. Reaktive Arthritis - Auf dem Weg zu einer erregerorientierten Ätiopathogenese und Klassifikation. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1043648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
50
|
Baumann M, Zeidler H, Rau R, Stroehmann I, Warnatz H. Low-Dose-Prednisolon-Therapie bei chronischer Polyarthritis. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1047316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|